Please login to the form below

Not currently logged in
Email:
Password:

Basilea appoints commercial head

David Veitch spent 15 years at BMS

Switzerland-based biopharma Basilea has appointed David Veitch as chief commercial officer, effective September 1, 2014.

Veitch will lead the company's commercial operations, including sales, marketing and pricing.

He joins from Savient Pharmacueticals where he served as president of the company's' European operations. It's at Bristol-Myers Squibb (BMS) where Veitch has spent most of his career, however, serving at the company from 1996 to 2011 when he joined Savient.

Veitch's most senior role at BMS was senior VP for EMEA marketing and brand commercialisation.

Ronald Scott, CEO of Basilea, commented that Veitch's “extensive experience and in-depth knowledge of European pharmaceutical markets will be instrumental” as the company prepares to launch its antibiotic Zevtera in Europe in 2015.

19th August 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics